Suppr超能文献

治疗性细胞因子或细胞因子调节剂与小分子药物之间潜在的药代动力学相互作用:通过体外系统研究的机制理解

Potential pharmacokinetic interactions of therapeutic cytokines or cytokine modulators on small-molecule drugs: mechanistic understanding via studies using in vitro systems.

作者信息

Zhou Jin, Li Feng

出版信息

Drug Metabol Drug Interact. 2014;29(1):17-28. doi: 10.1515/dmdi-2013-0028.

Abstract

The potential pharmacokinetic interactions between macromolecules and small-molecule drugs have received more and more attention with the increasing development of macromolecule therapeutics. Studies have shown that cytokines can differentially modulate drug-metabolizing enzymes and transporters, which raises concerns on the potential interactions of therapeutic cytokines and cytokine modulators on the disposition of small-molecule drugs. Although many in vitro studies have been conducted to characterize the effects of cytokines on drug-metabolizing enzymes and transporters, these studies were limited to only a handful of cytokines, such as interleukin-1 (IL-1), IL-6, tumor necrosis factor-α, and interferon. It is also challenging to translate these in vitro results to in vivo. In addition, information on the impact of cytokine modulators on drug-metabolizing enzymes and transporters is rather limited. More research is needed in this area. The present review is to provide a summary of the in vitro findings on the pharmacokinetic interactions of therapeutic cytokines and cytokine modulators on small-molecule drugs. Discussion on current challenges in assessing these interactions is also included.

摘要

随着大分子疗法的不断发展,大分子与小分子药物之间潜在的药代动力学相互作用受到了越来越多的关注。研究表明,细胞因子可对药物代谢酶和转运体产生不同的调节作用,这引发了人们对治疗性细胞因子和细胞因子调节剂与小分子药物处置之间潜在相互作用的担忧。尽管已经开展了许多体外研究来表征细胞因子对药物代谢酶和转运体的影响,但这些研究仅限于少数几种细胞因子,如白细胞介素-1(IL-1)、IL-6、肿瘤坏死因子-α和干扰素。将这些体外研究结果转化为体内研究结果也具有挑战性。此外,关于细胞因子调节剂对药物代谢酶和转运体影响的信息相当有限。该领域需要更多的研究。本综述旨在总结治疗性细胞因子和细胞因子调节剂与小分子药物药代动力学相互作用的体外研究结果。文中还讨论了评估这些相互作用时当前面临的挑战。

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型,支持多种主流文档格式。

立即体验